SOHO 2024: Focus on Myeloma

Melissa BadamoMyeloma | November 14, 2024
A study demonstrated favorable outcomes among high-risk patients with newly diagnosed MM who received HSCT consolidation.
Melissa BadamoMyeloma | November 14, 2024
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM.
Melissa BadamoMyeloma | November 14, 2024
Daratumumab-based induction therapy showed improved responses and comparable safety in newly diagnosed multiple myeloma.
Advertisement
Melissa BadamoMyeloma | November 14, 2024
Adding isatuximab to standard-of-care improved CR and MRD negativity rates in transplant-eligible, newly diagnosed MM.
Patrick DalyMyeloma | October 31, 2024
This real-world study characterized step-up dosing models for talquetamab in patients with multiple myeloma.
Patrick DalyMyeloma | October 31, 2024
Talquetamab and pomalidomide induced rapid and deep responses in patients with relapsed or refractory multiple myeloma.
Advertisement
Patrick DalyMyeloma | October 31, 2024
The iMMagine-3 randomized trial has begun enrollment of patients with relapsed or refractory multiple myeloma.
Patrick DalyMyeloma | October 31, 2024
OS, infections, hospitalization, and availability off the shelf were preferred treatment attributes of T-cell engagers.
Julie GouldMyeloma | October 1, 2024
MRD negativity is a strong predictor of better prognosis and survival in patients with MM.
Julie GouldMyeloma | October 1, 2024
Ongoing detection of TP53 mutations remains critical for accurate risk stratification and treatment planning in MM.
Julie GouldMyeloma | October 1, 2024
Patients with double-hit or triple-hit MM had significantly poorer outcomes compared to those with single-hit MM.
Julie GouldMyeloma | October 1, 2024
Novel agents such as belantamab mafodotin may improve PFS in patients with relapsed MM after anti-CD38 treatment.
Rob DillardMyeloma | September 18, 2024
Anito-cel showed "robust" efficacy in patients with relapsed or refractory multiple myeloma.
Rob DillardMyeloma | September 18, 2024
Myeloma in remission did not appear to affect myocardial infarction outcomes, but did affect resource utilization.
Rob DillardMyeloma | September 18, 2024
The latest data update on teclistamab in multiple myeloma continues to support strong efficacy and durable response.
Rob DillardMyeloma | September 18, 2024
The addition of daratumumab improved the performance of VRd in patients with newly diagnosed multiple myeloma.
Claire NowakMyeloma | September 13, 2024
The bispecific antibody was administered as a fourth-line treatment 12 years after the patient’s diagnosis.
Claire NowakMyeloma | September 13, 2024
Prior to the retrospective study presented at SOHO 2024, no study conducted a similar comparison of Dara-VTD and RVD.
Claire NowakMyeloma | September 13, 2024
Prior research suggested that weekly carfilzomib at a dose of 70 mg/m2 plus dexamethasone can increase PFS.
Claire NowakMyeloma | September 20, 2024
The phase III KarMMa-9 trial will review the efficacy of R maintenance alone versus with ide-cel in newly diagnosed MM.
Advertisement
Advertisement
Editorial Board